MAAE方案治疗复发难治急性白血病25例

目的 回顾性分析MAAE方案对复发难治急性白血病(AL)的疗效及毒副作用.方法 对25例复发难治AL患者,采用米托蒽醌(MIT)、阿糖胞苷(Ara-C)、安吖啶(AMSA)和依托泊苷(VP16)组成的MAAE方案治疗.用法:第1天至第3天,MIT 10 mg/d,静脉滴注;第1天至第7天,Ara-C 200 mg/d,静脉滴注;第1天至第3天,AMSA 75 mg/d,静脉滴注;第1天至第4天,VP16100 mg/d,静脉滴注,7 d为1个疗程.WBC＜0.5×109/L时使用粒细胞集落刺激因子(G-CSF)每天5 μg/kg直至WBC＞1.0×109/L.结果 经1～3个疗程,25例患者中14例完全缓解(CR),占56%,5例部分缓解(PR),占20%,总有效率为76%.结论 MAAE方案治疗复发难治AL疗效较好,主要毒副作用为骨髓抑制.

Treatment of refractory and relapsed acute leukemia in 25 adult patients with MAAE regimen

Objective To analyze on the efficacy and toxicity of MAAE (MIT ,Ara-C,AMSA,VP16)regimens on treating refractory and relapsed acute leukemia in adult patients. Methods MAAE (MIT, Ara-C,AMSA, VP16) regimen, which consisted of MIT 10mg/d (d1～3), intravenousdrop, Ara-C 200mg/d (d1～7),intravenousdrop, AMSA 75 mg/d (d1～3), intravenousdrop VP16 100 mg/d(d1～4), intravenousdrop were used to treat 25 cases of adults with refractory and relapsed acute leukemia (AL). G-CSF 5 μg/kg were used every day when WBC＜0.5×109/L. Results In the 25 cases with refractory and relapsed acute leukemia, 14 cases (56 %) reached complete remission, 5 patients(20 %) reached partial remission, the total effective rate was 76 %. Conclusion MAAE regimen was a very effective alternative treatment for CR induction in adult patients with refractory and relapsed AL and low toxicity.